Phase 1 N=12 Interpersonal Psychotherapy for Depressed Adolescents Engaging in Non-suicidal Self-injury
Depression · Self-injurious Behavior
Primary: CGI
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=41 Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children
Allergic Rhinitis · Upper Respiratory Infection
Primary: AUC of Doxylamine — 461.9; 810.1; 827.0 ng*h/mL
Phase 1 N=40 Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
Streptococcus Pneumoniae · Haemophilus Influenzae
Primary: Number of Subjects With Any Solicited Local and General Symptoms — 15; 16; 4; 10 Subjects
Phase 1 N=64 A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
Cancer
Primary: Maximum Tolerated Dose (MTD) of Eribulin Mesylate of E7389 in Combination With Carboplatin in Subjects With Advanced Solid Tumors. — 1.4; 1.1; 1.1 mg/m^2
Phase 1 N=58 Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet
Diabetes Mellitus, Type 2
Primary: Maximum Plasma Concentration (Cmax) — 901.82; 770.52 ng/ml
Phase 1 N=69 Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline — 54.30; 63.43 milligram per deciliter (mg/dL)
Phase 1 N=31 Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Systolic Blood Pressure at Day 5: 50 mg — -0.14; 8.94 mmHg
Phase 1 N=20 A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
Hepatitis C
Primary: Cmax (Maximum Observed Concentration in Plasma) of MP-424 — 1.62; 1.45; 3.96; 3.06 μg/mL
Phase 1 N=17 Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
Primary: The Primary Endpoint of the Study is to Establish the Maximum Tolerated Dose of Vorinostat When Given Concurrently With Palliative Radiation. — 400 mg
Phase 1 N=27 Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1) — 2; 3 participants
Phase 1 N=40 Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
Obesity
Primary: Changes in the VAS Score From Baseline. — 2.90; 2.70; -10.8; 6.70 mm
Phase 1 N=24 Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
Renal Impairment
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 268; 370; 396; 615 nanogram*hour/milliliter (ng*hr/mL)
Phase 1 N=71 Metabolic Signatures and Biomarkers in Schizophrenia
Schizophrenia
Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149
Phase 1 N=24 A Study Of CP-690,550 In Stable Kidney Transplant Patients
Kidney Transplant
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For CP-690,550 — 183; 754; 1200 nanogram*hour per milliliter (ng*hr/mL)
Phase 1 N=30 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
Schizophrenia · Bipolar I Disorder
Primary: Maximum Plasma Concentration (Cmax) of Asenapine — 1.84; 3.48; 9.24; 6.75 ng/mL